Sara Sharif’s injuries similar to car crash victim, court hears
Paediatric radiologist Prof Owen Arthurs noted that spinal fractures are rare and usually associated with high-impact trauma, such as from vehicle accidents.
The court heard that Sara had been subjected to over two years of abuse. (Photo: Surrey Police)
Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
A court was told that 10-year-old Sara Sharif sustained injuries similar to those typically seen in car crash victims prior to her tragic death.
During the trial, which is examining the circumstances of her death, it was revealed that Sara had over 70 injuries, including signs of healing spinal fractures that had been rebroken.
This information was presented to jurors by paediatric radiologist Prof Owen Arthurs, who noted that spinal fractures are rare and usually associated with high-impact trauma, such as from vehicle accidents.
He also mentioned that Sara's neck injuries were exceptionally unusual, suggesting they were most likely caused by manual strangulation, indicating significant force was used.
Sara’s dead body was discovered in her home in Woking, Surrey, in August 2023.
The Old Bailey previously heard of the severe abuse Sara endured over a period of more than two years. Testimonies indicated she had been hooded, burned, bitten, and physically beaten.
In addition to the spinal injuries, Sara exhibited signs of starvation and was found to have a broken bone in her neck. These findings raise grave concerns about her treatment in the weeks leading to her death.
Sara’s father, Urfan Sharif, 42, stepmother, Beinash Batool,30, and uncle Faisal Malik,29, are on trial for murder and have denied the charges. They also face accusations of causing or allowing the death of a child.
Prosecutors have highlighted the disturbing details of Sara's injuries, which included puncture wounds and bruising, alongside marks consistent with burns and scalding from hot water.
The prosecution argued that the trio's behaviour following Sara's death raises further suspicions. It was reported that they fled to Pakistan with Sara’s five siblings just a day before her body was found. Urfan called police from Pakistan, admitting his role in Sara's death approximately an hour after arriving there.
Testimonies in court also included details about the physical condition of Sara’s body. Bone expert Prof Anthony Freemont indicated that the fractures in her neck likely resulted from compression, a common cause of such injuries being manual strangulation.
He also noted that the presence of fractures of varying ages in different bones suggested a pattern of non-accidental injuries, underscoring the extent of the abuse Sara faced.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.